Lanoxin (Digoxin)

Digoxin inhibits the Na⁺/K⁺‑ATPase pump on heart muscle cells, leading to increased intracellular sodium. This change reduces the activity of the sodium‑calcium exchanger, causing calcium buildup that strengthens heart contractions and prolongs AV‑node refractory period, thereby slowing ventricular rate.

The dose of Lanoxin is individualized and determined by the prescribing clinician based on the patient’s age, renal function, electrolyte status, and therapeutic response. Dosing regimens are adjusted to achieve target serum digoxin concentrations while minimizing toxicity.

Lanoxin is classified as Pregnancy Category C, meaning risk cannot be ruled out. It should be used only when the potential maternal benefit justifies potential fetal risk. Digoxin is excreted in breast milk; breastfeeding decisions should be made after weighing benefits and possible infant exposure.

To order Lanoxin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

The primary alternative for rate control in atrial fibrillation is beta‑blockers, which act by reducing sympathetic stimulation. Unlike beta‑blockers, digoxin primarily enhances vagal tone and provides positive inotropy, making it useful in patients with concurrent heart failure where beta‑blockers alone may be insufficient.

Lanoxin must be stored at 2‑8 °C in a refrigerator, protected from light. The solution should not be frozen or shaken. Before use, inspect the vial for particulate matter and ensure the container remains sealed to maintain sterility.

Lanoxin is given by intravenous injection or infusion. The medication is administered slowly, typically over several minutes, under continuous cardiac monitoring to observe for arrhythmias or changes in heart rate. Administration should follow the prescriber’s specific instructions and institutional protocols.

The most critical risks include life‑threatening cardiac arrhythmias such as ventricular tachycardia, severe bradycardia, and various degrees of heart block. Early signs of digoxin toxicity—nausea, visual disturbances, and electrolyte imbalances—should prompt immediate medical evaluation.

Lanoxin is contraindicated in patients with ventricular fibrillation, known hypersensitivity to digoxin or other cardiac glycosides, and in those with uncontrolled atrial flutter or fibrillation where rapid ventricular response is required. Caution is also advised in patients with severe conduction disorders without a pacemaker.